Oncomed Pharmaceuticals (NASDAQ:OMED)‘s stock had its “neutral” rating reissued by HC Wainwright in a report released on Friday.
A number of other brokerages also recently issued reports on OMED. Zacks Investment Research downgraded Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Cantor Fitzgerald set a $6.00 price target on Oncomed Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. Oncomed Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $5.81.
Oncomed Pharmaceuticals (NASDAQ OMED) opened at $2.16 on Friday. Oncomed Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $10.89. The stock has a market capitalization of $81.77, a price-to-earnings ratio of -1.14 and a beta of 2.24.
Institutional investors have recently bought and sold shares of the company. Hodges Capital Management Inc. boosted its position in shares of Oncomed Pharmaceuticals by 155.9% in the 3rd quarter. Hodges Capital Management Inc. now owns 25,592 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 15,592 shares in the last quarter. BlueCrest Capital Management Ltd acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter worth $133,000. Paloma Partners Management Co acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter worth $135,000. Virtu Financial LLC acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter worth $170,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Oncomed Pharmaceuticals by 89.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 24,653 shares in the last quarter. 36.19% of the stock is owned by hedge funds and other institutional investors.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.